<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To report an interaction between <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) and <z:chebi fb="0" ids="10023">voriconazole</z:chebi> resulting in <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>SETTING: Hospital in Huntsville, AL, in November 2007.Patient description: 21-year-old black woman admitted to the hospital for <z:hpo ids='HP_0001945'>fever</z:hpo> in the setting of <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>CASE SUMMARY: The patient had been diagnosed with <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo> 5 months before admission and continued on ATRA throughout induction and two consolidation therapies </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="10023">Voriconazole</z:chebi> was started in view of persistent <z:hpo ids='HP_0001945'>fever</z:hpo> and <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> despite adequate broad-spectrum antimicrobial therapy </plain></SENT>
<SENT sid="4" pm="."><plain>On day 15 of <z:chebi fb="0" ids="10023">voriconazole</z:chebi> therapy, the patient complained of <z:hpo ids='HP_0000622'>blurred vision</z:hpo>, <z:hpo ids='HP_0000540'>farsightedness</z:hpo>, and <z:hpo ids='HP_0000958'>dry skin</z:hpo> with <z:hpo ids='HP_0000989'>pruritus</z:hpo> and was subsequently diagnosed with <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> secondary to ATRA toxicity </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> symptoms of <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> resolved after discontinuation of ATRA.Main outcome measures: Not applicable </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The development of <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> after initiation of <z:chebi fb="0" ids="10023">voriconazole</z:chebi> may have been secondary to the inhibition of the <z:chebi fb="0" ids="38559">cytochrome P450</z:chebi> (<z:chebi fb="0" ids="38559">CYP</z:chebi>) enzymes </plain></SENT>
<SENT sid="7" pm="."><plain>The interaction may have led to changes in ATRA serum concentrations, thus contributing to the observed adverse drug reaction </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: To our knowledge, this is the first case report of <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> in an adult patient secondary to metabolic inhibition of ATRA by <z:chebi fb="0" ids="10023">voriconazole</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>This case illustrates the importance of monitoring for drug interactions when using medications metabolized via the <z:chebi fb="0" ids="38559">CYP</z:chebi> enzyme pathway </plain></SENT>
</text></document>